Connor, Clark & Lunn Investment Management Ltd. Catalyst Pharmaceuticals, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$26 Billion
Q2 2025

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 95,005 shares of CPRX stock, worth $1.95 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

95,005

Previous 161,272 41.09%

Holding current value

$1.95 Million

Previous $3.91 Million 47.29%

% of portfolio

0.01%

Previous 0.02%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 07, 2025	SELL	$21.4 - $26.31 $1.42 Million - $1.74 Million	-66,267 Reduced 41.09%	95,005 $2.06 Million
Q1 2025 May 12, 2025	BUY	$19.53 - $25.74 $3.15 Million - $4.15 Million	161,272 New	161,272 $3.91 Million
Q3 2024 Nov 08, 2024	BUY	$15.19 - $21.35 $152,765 - $214,716	10,057 New	10,057 $199,000
Q1 2023 May 09, 2023	BUY	$14.34 - $21.05 $2.34 Million - $3.43 Million	163,060 Added 545.97%	192,926 $3.2 Million
Q4 2022 Feb 10, 2023	SELL	$12.25 - $19.5 $895,989 - $1.43 Million	-73,142 Reduced 71.01%	29,866 $555,000
Q3 2022 Nov 10, 2022	BUY	$7.06 - $15.52 $727,236 - $1.6 Million	103,008 New	103,008 $1.32 Million
Q2 2022 Aug 05, 2022	SELL	$6.23 - $8.57 $152,205 - $209,373	-24,431 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$5.31 - $8.31 $62,870 - $98,390	-11,840 Reduced 32.64%	24,431 $203,000
Q4 2021 Feb 10, 2022	BUY	$5.21 - $7.45 $188,971 - $270,218	36,271 New	36,271 $246,000
Q2 2020 Aug 13, 2020	SELL	$3.48 - $5.05 $170,694 - $247,702	-49,050 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$2.61 - $5.21 $128,020 - $255,550	49,050 New	49,050 $188,000
Q3 2019 Nov 13, 2019	SELL	$3.89 - $7.43 $55,751 - $106,486	-14,332 Closed	0 $0
Q2 2019 Aug 07, 2019	BUY	$2.7 - $6.11 $38,696 - $87,568	14,332 New	14,332 $55,000
Q1 2019 May 08, 2019	SELL	$2.11 - $5.33 $77,437 - $195,611	-36,700 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$1.92 - $3.62 $10,920 - $20,590	5,688 Added 18.34%	36,700 $70,000
Q3 2018 Nov 13, 2018	BUY	$2.81 - $3.78 $16,893 - $22,725	6,012 Added 24.05%	31,012 $117,000
Q2 2018 Aug 02, 2018	BUY	$2.26 - $3.84 $56,499 - $96,000	25,000 New	25,000 $78,000

Others Institutions Holding CPRX

# of Institutions

386

Shares Held

103M

Call Options Held

Put Options Held

277K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.11B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Catalyst Pharmaceuticals, Inc. Transaction History